Chi, Kim NKim NChiRathkopf, DanaDanaRathkopfSmith, Matthew RMatthew RSmithEfstathiou, EleniEleniEfstathiouAttard, GerhardtGerhardtAttardOlmos, DavidDavidOlmosLee, Ji YoulJi YoulLeeSmall, Eric JEric JSmallPereira de Santana Gomes, Andrea JAndrea JPereira de Santana GomesRoubaud, GuilhemGuilhemRoubaudSaad, MarnizaMarnizaSaadZurawski, BogdanBogdanZurawskiSakalo, ValeriiValeriiSakaloMason, Gary EGary EMasonFrancis, PeterPeterFrancisWang, GeorgeGeorgeWangWu, DaphneDaphneWuDiorio, BrookeBrookeDiorioLopez-Gitlitz, AngelaAngelaLopez-GitlitzSandhu, ShahneenShahneenSandhuYU-CHIEH TSAI2024-01-102024-01-102023-06-200732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/638368Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition.en[SDGs]SDG3journal article10.1200/JCO.22.01649369526342-s2.0-85161255306https://api.elsevier.com/content/abstract/scopus_id/85161255306